GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Efficacy Study of Protein Supplementation in Attenuating the Decline in Performance After Strenuous Concurrent Exercise

Not Applicable

Completed

Conditions: Sports Nutritional Sciences

Interventions: Dietary Supplement: Reference product 1
Dietary Supplement: Test product
Dietary Supplement: Reference product 2

First Posted Date: 2015-06-01

Last Posted Date: 2016-08-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT02458599

Locations: 🇬🇧
GSK Investigational Site, Brentford, United Kingdom

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Danirixin HBr 50 mg IR Tablet
Drug: Danirixin FB 50 mg IR Tablet
Drug: Prilosec (omeprazole) 40mg Delayed-Release capsule

First Posted Date: 2015-05-25

Last Posted Date: 2018-07-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT02453022

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

Phase 2

Completed

Conditions: Infections, Meningococcal
Meningococcal Disease

Interventions: Biological: MenABCWY+OMV vaccine

First Posted Date: 2015-05-22

Last Posted Date: 2020-07-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 129

Registration Number: NCT02451514

Locations: 🇵🇦
GSK Investigational Site, Panama City, Panama

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2015-05-19

Last Posted Date: 2018-09-14

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02447939

Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis

Not Applicable

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Device: Faros Sensor (FS) and LifeInsight Hub
Device: Fast Fix electrode patch
Procedure: Quantitative Measure of Speech (Core Phase Only)

First Posted Date: 2015-05-19

Last Posted Date: 2018-12-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 25

Registration Number: NCT02447952

Locations: 🇬🇧
GSK Investigational Site, Oxford, United Kingdom

Duration of Protection: GSK DTaP Vaccines

Completed

Conditions: Diphtheria
Tetanus
Acellular Pertussis

Interventions: Biological: Infanrix
Biological: Pediarix
Biological: Kinrix

First Posted Date: 2015-05-19

Last Posted Date: 2015-11-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT02447978

A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)
Biological: Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)
Biological: DTPw-HBV/Hib